When the SUCCESSOR-2 trial read out its 52% progression-free survival advantage for mezigdomide, elotuzumab, and dexamethasone over carfilzomib and dexamethasone, it did more than confirm a new regimen—it answered a question that has haunted the myeloma field since the IMiD era began: can you meaningfully reset immune substrate in a lenalidomide-exhausted patient?
The CELMoD mechanism answers yes, at least immunologically. Mezigdomide degrades IKZF1/3 roughly ten times more potently than lenalidomide and retains binding to the mutated forms of CRBN that confer IMiD resistance. The SUCCESSOR-2 hazard ratio of 0.48 against carfilzomib and dexamethasone—a credible active comparator—says the immune reset is clinically meaningful.
The trial’s design choice to use Kd as the control arm deserves attention. Kd is a proteasome inhibitor doublet, not a triplet, making it somewhat vulnerable as a benchmark. But in the triple-class-exposed setting, a PI doublet is often the best available standard-of-care option; the investigators chose what patients actually receive, not the most favorable optic.
What SUCCESSOR-2 does not yet tell us is where MEd sits relative to CAR-T constructs in any head-to-head comparison, what happens at progression after MEd, or whether elotuzumab is additive to mezigdomide or merely synergistic in certain subgroups. The subgroup consistency was reassuring—benefit persisted in patients with high-risk cytogenetics—but the trial was not powered for these analyses.
For community oncologists, the practical read is straightforward: MEd offers a meaningful progression-free survival advantage in a population with few good options. Whether it becomes the standard bridge to CAR-T or a longer-term option will depend on overall survival data that are not yet mature and on access realities that differ by healthcare system.
The CELMoD era in myeloma is no longer theoretical. SUCCESSOR-2 is its defining registration dataset.